FDA grants authorization for Novavax Covid vaccine directed against JN.1 variant
Introducing Novavax’s Protein-Based COVID-19 Vaccine The Food and Drug Administration (FDA) recently authorized Novavax’s updated protein-based COVID-19 vaccine for emergency use in individuals ages 12 and up. This development opens up a new option for … Read more
